Fulcrum Posts $26.2M Q2 Loss, $318.8M Cash; Restructuring Charges Hit $9.4M
FULC sits 30% above its 52-week low of $2.83.
Summary
Fulcrum's Q2 2026 10-Q reveals a $26.2M net loss, $9.4M in restructuring and impairment charges, and $318.8M in cash. The company is now a shell seeking a strategic transaction, with liquidation possible if no deal materializes.
Key Events · Earnings and Guidance · FULC
-
Q2 Net Loss of $26.2M
Driven by $5.1 million in asset impairments and $4.3 million in restructuring charges following the pociredir discontinuation, the net loss widened to $26.2 million from $17.3 million a year ago.
-
Cash Runway into 2029
Cash, equivalents, and marketable securities totaled $318.8 million at June 30, 2026. Management expects this to fund operations into 2029, but the estimate assumes no new R&D spending and a successful strategic transaction.
-
Restructuring and Impairment Charges
The company recorded $4.3 million in severance and related costs for the 85% workforce reduction, plus $5.1 million in impairments for its leased facility and lab equipment.
-
Pre-Funded Warrants Exercised
All outstanding pre-funded warrants were exercised during Q2, adding approximately 9.6 million shares to the outstanding count, which rose to 76.3 million from 66.6 million at year-end.
Analysis · FULC · Life Sciences
The first quarterly report since Fulcrum discontinued its lead drug and cut 85% of its workforce lays bare the financial damage: a $26.2 million net loss for Q2, weighed down by $5.1 million in asset impairments and $4.3 million in severance costs. Cash and investments stood at $318.8 million at the end of June, which management believes can fund operations into 2029—but that runway hinges on no new development spending and a successful strategic transaction. The filing also reveals that all outstanding pre-funded warrants were exercised, adding roughly 9.6 million shares, and that retention bonuses and enhanced change-in-control benefits were approved for remaining executives. This signals a board intent on preserving a skeleton crew for a potential sale or merger. Notably, the risk factors now explicitly warn that if no strategic alternative emerges, the board may pursue dissolution and liquidation.
At the time of this filing, FULC was trading at $3.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $247.9M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.